Herbalife and IIT Madras Launch India's First Centre of Excellence on Plant Cell Fermentation Technology

Product / TechIndustry
โดย PRNewswire·Read original
Summary · why it matters

Herbalife and IIT Madras have inaugurated India's first dedicated facility for translational research in plant cell fermentation technology. The Herbalife–IIT Madras Centre of Excellence, launched on 22nd June 2026 at IIT Madras Research Park, aims to position India as a global leader in sustainable biomanufacturing and next-generation plant-derived health and wellness products. The centre will focus on scalable production of herbal biomass, development of enriched extracts and high-value phytochemicals, and bridging the gap between lab discoveries and industrial applications. It is equipped with customized plant cell bioreactors, advanced analytical platforms, and pilot-scale processing facilities. The initiative aligns with India's BioE3 and Atmanirbhar Bharat missions and is expected to foster academia-industry collaborations, intellectual property generation, and entrepreneurship.

Impact on stocks 1

Consumer Staples · 1 stocks
Herbalife Nutrition Ltd
HLF
▲ PositiveTechnologyrelevance

Herbalife launches a Centre of Excellence with IIT Madras for plant cell fermentation technology, advancing its R&D and positioning in sustainable biomanufacturing.

Theme Impact 2

Related news

Biological Computing Market to Reach $2.9 Billion by 2026

The global biological computing market is projected to grow from $2.21 billion in 2025 to $2.90 billion in 2026, a compound annual growth rate of 31.2%, according to a new report from ResearchAndMarkets.com. The market is forecast to reach $8.64 billion by 2030, expanding at a CAGR of 31.4% from 2026. Growth is driven by advances in DNA sequencing, synthetic biology, and bioinformatics, as well as demand for energy-efficient computing and personalized medicine. Key trends include DNA-based computing, synthetic biology-driven systems, and hybrid biological-digital platforms. Notable developments include FinalSpark's Neuroplatform for cloud-based biocomputing with human brain organoids and a partnership between VERSES Technologies and Cortical Labs to integrate AI with living neurons. North America led the market in 2025, while Asia-Pacific is expected to grow fastest. The report profiles major players such as Thermo Fisher Scientific, Illumina, and Ginkgo Bioworks.
GlobeNewswire·18dRead more →
2

Chuanning Biology first-half net profit 278 million yuan, synthetic biology revenue up 221%

Chuanning Biology disclosed its 2026 semi-annual report. In the first half of the year, it achieved total operating revenue of 2.098 billion yuan and net profit attributable to shareholders of the listed company of 278 million yuan. Second-quarter net profit was 167 million yuan, roughly flat compared with the same period last year and steadily higher than the first quarter. The company's synthetic biology production base in Gongliu County, Xinjiang, achieved operating revenue of 71.7599 million yuan in the first half, up 221.38% year on year. High-value-added products such as bisabolol, ergothioneine and squalane have already reached large-scale production. Domestic approval of ergothioneine as a new food ingredient has entered a critical stage and is expected to be formally approved in the second half of 2026.
证券时报·26dRead more →
5

Cathay Biotech first-half net profit 372 million yuan, up 20.75% year on year

Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.
上海证券报·30dRead more →